Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
mediaposted on 2023-05-11, 22:23 authored by Adis Journals on behalf of:, Sahil Khanna, Maha Assi, David Yoho, Thomas Louie, Whitfield Knapple, Humberto Aguilar, Julia Garcia-Diaz8, Gary P. Wang, Scott M Berry, Joe Marion, Xin Su, Tricia Braun, Lindy Bancke, Paul Feuerstadt
Article full text
The above slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC